Nachrichten zur Sarepta Therapeutics Aktie

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns

…

Is Sarepta Therapeutics Stock a Bad-News Buy? @themotleyfool #stocks $SRPT

Analysts still expect some sizable returns from the stock.…

Is Sarepta Therapeutics Stock a Bad-News Buy?

Analysts still expect some sizable returns from the stock.…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2023.…

SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues…

Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript

…

Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M

…

Sarepta Therapeutics Q3 2023 Earnings Preview

…

Sarepta Therapeutics, Petmed Express among healthcare movers

…

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades By Investing.com

Sarepta Therapeutics crushed after EMBARK misses primary endpoint, promoting 2 downgrades…

: Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal

Company plans to seek label expansion for Duchenne muscular dystrophy treatment…

How to Invest in Genetics (Updated 2023)

Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

…

Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester

Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…

Is Sarepta Therapeutics Stock a Top Growth Vehicle?

An upcoming data readout could fuel another rally in the biotechs shares....…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 1.092.429$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-14...…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 2.559.272$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-11...…

Insiderhandel: Aufsichtsrat kauft Aktien von Sarepta Therapeutics im Wert von 3.701.067$

Chambers, Michael Andrew - Aufsichtsrat - Tag der Transaktion: 2023-08-10...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Sarepta Therapeutics im Wert von 1.600.800$

Wigzell, Hans Lennart Rudolf - Aufsichtsrat - Tag der Transaktion: 2023-08-04...…

Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript

SRPT earnings call for the period ending June 30, 2023....…

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do…

Sarepta Therapeutics Q2 Loss Decreases, beats estimates

WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for second quarter that decreased from the same period last year and…

Sarepta (SRPT) Sells Priority Review Voucher for $102M

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDAs approval to Elevidys gene therapy for treating…

Sarepta raises $102M from selling priority review voucher

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta Therapeutics completes sale of priority review voucher for $102 million

Sarepta Therapeutics Inc. SRPT said Wednesday it has completed the sale of its Rare Pediatric Disease Priority Review Voucher for…

Sarepta slumps as concerns emerge around upcoming gene therapy data

...June 23 (Reuters) - Sarepta Therapeutics shares slumped 11% on Friday......…

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics

Latest Ratings for SRPT DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022RBC CapitalMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight View…

FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy

WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. announced Friday that the U.S. Food and Drug Administration or FDA has accelerated approval…

FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced Friday that the U.S. Food and Drug Administration or FDA has accelerated approval of ELEVIDYS (delandistrogene…

Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy

Sarepta Therapeutics Inc. SRPT , which yesterday scored a win with U.S. Food and Drug Administration approval of the first…

Roche-Partner Sarepta erhält US-Zulassung für DMD-Therapie

Pharma - Der amerikanische Lizenzpartner von Roche, Sarepta, hat von der Gesundheitsbehörde FDA die Zulassung für seine Gentherapie Elevidys in…

The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million

The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder, but is…

Form 8-K Sarepta Therapeutics, For: Jun 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

XFRA : AB3A: Wiederaufnahme/Resumption

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…

Sarepta gets FDA approval for rare genetic disorder treatment

Sarepta Therapeutics Inc. SRPT said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the…

XFRA : INSTRUMENT_SUSPENSION - US8036071004

Instrument ID [10661] (AB3A - US8036071004) suspended...…

XFRA : AB3A: Aussetzung/Suspension

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME …

Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

The FDA extends the review period for Sareptas (SRPT) BLA for DMD gene therapy by almost four weeks to Jun…

Scholar Rock extends slide amid concerns over Sarepta gene therapy approval

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates

Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both…

Sarepta Therapeutics shares fall as FDA delays decision on gene ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of Sarepta Therapeutics Are Dropping Wednesday

The FDA told the company that a review of a new therapy will take nearly a month longer....…

Sarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy.

Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning…

Sarepta says FDA needs more time to review muscular dystrophy drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…